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month study. All study nurses expressed their preference for this
design versus a traditional nurse interview, paper-based design,
primarily due to decreased site burden in relation to data col-
lection. CONCLUSIONS: The use of a prospective diary and
IVRS data entry by the elderly is feasible and offers the possi-
bility to collect detailed prospective health economic data with
a minimum of burden to site study staff.
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OBJECTIVES: To estimate health care costs of patients with
partial refractory epilepsy (PRE) in the Mexican Institute of
Social Security (IMSS). METHODS: PRE requires long-term
health costly care with two or more anti-epileptic drugs, pres-
ence of intolerance and side effects. Case series with PRE diag-
nosis in four hospitals in Mexico City which inclusion criteria
were: aged 12 and older, using two or more anti-epileptic drugs
and information available of at least one-year follow-up period.
Cost evaluation perspective was that from services provider, 
time horizon was one year and three costing techniques were
combined: micro-costing, average cost and cost per diem, using
a bottom-up aproach. Costs are expressed in 2004 USD.
RESULTS: From medical records (813), 133 were correctly diag-
nosed as PRE and 72 cases met inclusion criteria. Demographic
characteristics: 58% were females, 64% were between 12–35
years old, 47% students, 58% single and 73% had intermediate
or preparatory education. Fifty one percent had simple partial
seizures and 94% more than one crisis per month. Mean annual
visits per patient to general practitioner was 5.2 and to neurol-
ogists 6.8; laboratory tests 6.0 and electroencephalographic
studies 0.8. Total annual cost of health care was $2646 per
patient and 24% was derived from hospitalisation. Total cost
was distributed in: 39% visits, 24% drugs, 21% bed days and
16% diagnostic tests. First line drugs were Carbamazepine 
and Valproic acid (more than 68%), while second line ones 
Clonazepam (36%), Lamotrigine (33%) and Topiramate (21%).
CONCLUSIONS: Most of patients were young, in productive
age and had more than one seizure per month; this is a matter
of concern because a difﬁcult seizure control affects negatively
patient and family social life, including employment. Effective-
ness, safety and cost of available drugs are crucial issues in
control and quality of life of PRE patients.
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OBJECTIVE: To evaluate the psychometric properties of 
disease-speciﬁc quality of life (QOL) instruments in epilepsy.
METHODS: A comprehensive search for epilepsy-speciﬁc QOL
instruments identiﬁed 13 metrics using MEDLINE, Pubmed,
International Pharmacy Abstracts, Google and reference lists.
QOL instruments were included in the study for evaluation if
there was at least one publication using the instrument includ-
ing psychometric data, in addition to instrument availability.
Instruments were evaluated based on criteria developed by
McHorney and Tarlov (1995) and Davis and Pathak (2001). The
seven domains considered in the evaluation were: item informa-
tion, practicality, breadth and depth of health measured, relia-
bility, validity, and responsiveness. RESULTS: Of the 13 QOL
instruments identiﬁed, adequate data was available to evaluate
ﬁve based on study criteria. The ﬁve epilepsy-speciﬁc QOL
metrics were: Quality of Life in Newly Diagnosed Epilepsy
(NEWQOL), Epilepsy Surgery Inventory (ESI-55), and the
Quality of Life in Epilepsy Inventory (QOLIE) series (-89, -31,
and -10). None of these ﬁve QOL metrics satisﬁed all the study
criteria. The QOLIE-31 reported adequate or better performance
in six of the seven domains assessed (omitting instrument
breadth). The QOLIE-10 reported adequate or better perfor-
mance in ﬁve of the seven domains assessed (omitting instrument
breadth and internal consistency). The QOLIE-10 and -31 offer
practical advantages over the longer QOLIE-89 metric with
QOLIE-31 showing superior psychometric properties based on
study results. CONCLUSIONS: Epilepsy is a chronic, socially
stigmatizing condition with potentially signiﬁcant affects on
patient QOL. A variety of instruments have been published in
the literature with QOLIE-89 most commonly used. Of the data
available for QOLIE series, the length of the QOLIE-89 limits
its use in clinical decision making, while the brevity of QOLIE-
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OBJECTIVES: A composite outcome measure in migraine treat-
ment assessment is useful to clinical decision makers and payers
as it provides a more accurate reﬂection of effectiveness and
allows for more complete modeling of economic value. This
composite measure must consider both short- and long-term
treatment effects, as well as placebo effects. The objective of this
study was to compare the total triptan cost to treat 100 migraine-
patient attacks and the cost per successfully treated patient
(CPSTP) for six marketed triptans using a composite measure 
of effectiveness, the ‘successfully treated’ migraine (deﬁned as
requiring only one triptan dose to treat one migraine attack
during a 24-hour period). METHODS: This analysis was con-
ducted from the perspective of the payer. Clinical data were
abstracted from a rigorous, published meta-analysis. Two-hour
response and pain-free response were used in conjunction with
the recurrence rate reported in the meta-analysis to calculate the
number of doses used by treatment successes and failures. The
average wholesale price per dose was then used to calculate total
triptan cost. RESULTS: Of the nine oral triptan doses compared,
eletriptan 40mg was associated with both the lowest total triptan
cost for treating 100 migraine attacks ($1560) and with the
lowest CPSTP ($56.39). CONCLUSIONS: The relative CPSTP
for migraine therapies is dependent on the deﬁnition of treatment
success and relative pricing. When success is deﬁned as using one
triptan dose to treat one migraine attack in a 24-hour period,
the triptans with the most value to managed care organizations,
in terms of cost per successfully treated patient, are eletriptan 
40mg ($56.39), zolmitriptan 2.5mg ($75.62) and sumatriptan
50mg ($77.59).
